Skip to main content

White paper - 5 essential capabilities for decentralized clinical trials

White paper

5 essential capabilities for decentralized clinical trials

As the clinical research landscape evolves, decentralized clinical trials (DCTs) have emerged as a foundational competency, enabling broader patient participation, increasing trial efficiency, and driving more inclusive, real-world data collection. However, the successful execution of DCTs requires more than just innovative technology—it demands a comprehensive strategy that addresses the unique challenges of decentralization.
Male patient lifestyle image

Understanding the essential capabilities for decentralized clinical trials

In our latest white paper, “5 essential capabilities for decentralized clinical trials,” we explore the critical components that pharmaceutical companies and Contract Research Organizations (CRO) must master to effectively transition to a decentralized model. From leveraging real-world data and expanding participant access through mobile phlebotomy, to ensuring robust patient engagement and maintaining the integrity of clinical trials testing, this white paper provides insights into the capabilities that are becoming increasingly important.

Whether you’re seeking to overcome the logistical hurdles of remote trials or aiming to enhance the diversity and inclusivity of your participant pool, this white paper provides actionable insights and practical guidance to help you navigate the complexities of DCTs.

Equip your organization with the knowledge to optimize your clinical trial strategies. Download the white paper today and discover how Quest Diagnostics can support your success in decentralized trials.

Advance your trials: essential strategies for DCT success

746

* indicates required